secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255166
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track
--------------------------------------------------------------------------------

- Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.
- Net loss of $17.5M for Q3 2024 vs $22.8M in Q3 2023 (prior year included $13.3M non-cash charge).
- IPO in Sep 2024 raised ~$362M gross from 20.125M shares at $18.00; listed on Nasdaq as BCAX.
- Pivotal Phase 2/3 trial FORTIFI-HN01 of ficerafusp alfa in 1L R/M HNSCC expected to start late Q4 2024 or early Q1 2025.
- Phase 1/1b data showed 64% ORR, 18% CR, median PFS 9.8 months in frontline HPV-negative R/M HNSCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/0001193125-24-255166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/d793839d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer